Shimizu Hiroyuki, Takeda Naokazu
Department of Virology II, National Institute of Infectious Diseases.
Nihon Rinsho. 2008 Oct;66(10):1950-5.
During the final stage of global polio eradication, universal use of inactivated poliovirus vaccine (IPV) might be one of the feasible options to minimize the inherent risk of oral polio vaccine (OPV), such as vaccine-associated paralytic poliomyelitis and polio outbreaks due to vaccine-derived polioviruses. A unique IPV, derived from attenuated polioviruses (Sabin IPV), has been developing in Japan, as a promising polio vaccine candidate, particularly in developing countries in the future. Thus, further polio immunization strategies, including the introduction of Sabin IPV, instead of OPV, to Japan and to developing countries, should be carefully considered.
在全球消灭脊髓灰质炎的最后阶段，普遍使用灭活脊髓灰质炎病毒疫苗（IPV）可能是将口服脊髓灰质炎疫苗（OPV）的固有风险降至最低的可行选择之一，例如疫苗相关麻痹性脊髓灰质炎以及由疫苗衍生脊髓灰质炎病毒引起的脊髓灰质炎疫情。一种源自减毒脊髓灰质炎病毒的独特IPV（萨宾IPV）正在日本研发，作为一种有前景的脊髓灰质炎疫苗候选产品，尤其在未来的发展中国家。因此，应仔细考虑进一步的脊髓灰质炎免疫策略，包括在日本和发展中国家引入萨宾IPV而非OPV。
